133 related articles for article (PubMed ID: 11951812)
21. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
22. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
[TBL] [Abstract][Full Text] [Related]
23. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
[TBL] [Abstract][Full Text] [Related]
24. Troglitazone: an antidiabetic agent.
Chen C
Am J Health Syst Pharm; 1998 May; 55(9):905-25. PubMed ID: 9588250
[TBL] [Abstract][Full Text] [Related]
25. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
[TBL] [Abstract][Full Text] [Related]
26. Effect of acarbose on blood glucose profiles and plasma 1,5-anhydro-d-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapy.
Hotta N; Koh N; Sakakibara F; Naruse K; Yamada T; Takeuchi N; Yamada K; Fukasawa H; Kakuta H
Biomed Pharmacother; 1996; 50(6-7):297-302. PubMed ID: 8952871
[TBL] [Abstract][Full Text] [Related]
27. Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
Inzucchi SE
JAMA; 2002 Jan; 287(3):360-72. PubMed ID: 11790216
[TBL] [Abstract][Full Text] [Related]
28. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.
Buysschaert M; Bobbioni E; Starkie M; Frith L
Diabet Med; 1999 Feb; 16(2):147-53. PubMed ID: 10229309
[TBL] [Abstract][Full Text] [Related]
29. New oral therapies for type 2 diabetes.
Purnell JQ; Hirsch IB
Am Fam Physician; 1997 Nov; 56(7):1835-42. PubMed ID: 9371013
[TBL] [Abstract][Full Text] [Related]
30. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD; Campbell LK; Campbell RK
Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
[TBL] [Abstract][Full Text] [Related]
31. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
32. The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus.
Huang EA; Gitelman SE
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):69-73. PubMed ID: 18221433
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the pharmacologic management of diabetes mellitus.
Carlton FB
Emerg Med Clin North Am; 2000 Nov; 18(4):745-53. PubMed ID: 11130936
[TBL] [Abstract][Full Text] [Related]
34. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.
López-Alvarenga JC; Aguilar-Salinas CA; Velasco-Perez ML; Arita-Melzer O; Guillen LE; Wong B; Brito G; Mercado V; Gómez-Pérez FJ; Rull-Rodrigo JA
Diabetes Obes Metab; 1999 Jan; 1(1):29-35. PubMed ID: 11221809
[TBL] [Abstract][Full Text] [Related]
35. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
[TBL] [Abstract][Full Text] [Related]
36. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Ciaraldi TP; Kong AP; Chu NV; Kim DD; Baxi S; Loviscach M; Plodkowski R; Reitz R; Caulfield M; Mudaliar S; Henry RR
Diabetes; 2002 Jan; 51(1):30-6. PubMed ID: 11756319
[TBL] [Abstract][Full Text] [Related]
37. [Troglitazone].
Yamanouchi T
Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
[TBL] [Abstract][Full Text] [Related]
38. Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Yokoyama I; Yonekura K; Moritan T; Tateno M; Momose T; Ohtomo K; Inoue Y; Nagai R
J Nucl Med; 2001 Jul; 42(7):1005-10. PubMed ID: 11438619
[TBL] [Abstract][Full Text] [Related]
39. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
[TBL] [Abstract][Full Text] [Related]
40. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
